Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish a RMB 5 billion (USD 695 million) fund in collaboration with seven other investors, with Shenzhen FOF expected to contribute 50% of the total funding.
The initiative aims to enhance resource sharing and cooperation between Fosun Pharma and Shenzhen, expanding opportunities for enterprises to engage in the healthcare sector, particularly in biopharmaceuticals. The fund will primarily target investments in Shenzhen, focusing on biopharmaceuticals, as well as cell and gene therapies. Notably, at least 70% of the fund’s investments will be allocated to the biopharmaceutical sector.
The Fosun Health Fund, launched by Fosun Pharma last year, serves as a management institution for biomedical industry investments in Shenzhen. This move aligns with the local government’s recent efforts to foster the growth of the biomedicine and healthcare industries through a series of supportive measures.- Flcube.com
